|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 546.00 CHF | -2.36% |
|
-3.50% | +1.52% |
| 14/01 | Lonza Group AG Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 10:30 AM | |
| 18/12 | Swiss trade surplus at CHF 3.841 bln in November | RE |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Life Sciences Tools and Services | ||||||||||
Biologics | - | 272.5Cr | 328Cr | 372.4Cr | 368Cr | |||||
CAPEX | - | -92Cr | -126Cr | -106.3Cr | -82Cr | |||||
EBITDA | - | 98Cr | 122.8Cr | 129.4Cr | 126.6Cr | |||||
D&A | - | 17Cr | 22Cr | 25Cr | 31Cr | |||||
Advanced Synthesis | - | 77Cr | 82Cr | 90Cr | 98Cr | |||||
CAPEX | - | -12Cr | -18Cr | -16Cr | -13Cr | |||||
EBITDA | - | 22Cr | 25Cr | 28Cr | 35Cr | |||||
D&A | - | 5.6Cr | 6Cr | 6.2Cr | 7.1Cr | |||||
Specialized Modalities | - | 65Cr | 74Cr | 76Cr | 74Cr | |||||
CAPEX | - | -8.4Cr | -11Cr | -9Cr | -18Cr | |||||
EBITDA | - | 11Cr | 12Cr | 6.4Cr | 11Cr | |||||
D&A | - | 5.1Cr | 6.4Cr | 6.6Cr | 7.2Cr | |||||
Pharma Biotech & Nutrition | 449.8Cr | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | -80Cr | - | - | - | - | |||||
EBITDA | 143.6Cr | - | - | - | - | |||||
D&A | 41Cr | - | - | - | - | |||||
Operating Income | 101Cr | - | - | - | - | |||||
Pharmaceutical Products | ||||||||||
Capsules & Health Ingredients | - | 122Cr | 126.9Cr | 116.2Cr | 105.5Cr | |||||
CAPEX | - | -8.3Cr | -9.6Cr | -7.3Cr | -8.1Cr | |||||
EBITDA | - | 41Cr | 42Cr | 33Cr | 26Cr | |||||
D&A | - | 18Cr | 18Cr | 17Cr | 17Cr | |||||
Capsugel | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Corporate/Eliminations | 1Cr | 4.2Cr | 11Cr | 17Cr | 11Cr | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | -80L | -5.3Cr | -18Cr | -27Cr | -16Cr | |||||
EBITDA | -3.6Cr | -4.9Cr | -1.5Cr | 3.1Cr | -7.3Cr | |||||
D&A | 4.8Cr | 6.5Cr | 7.7Cr | 7.1Cr | 2.7Cr | |||||
Operating Income | -11Cr | - | - | - | - | |||||
Vitamins and Nutritional Supplements | ||||||||||
Specialty Ingredients | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
CAPEX | - | - | - | - | - | |||||
EBITDA | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 256.8Cr | 211.7Cr | 241.5Cr | 213.6Cr | 230.9Cr | |||||
Total Assets | 302.1Cr | 234.6Cr | 255.9Cr | 233.8Cr | 368Cr | |||||
Switzerland | 64Cr | 66Cr | 100Cr | 116.8Cr | 72Cr | |||||
Total Assets | 223.9Cr | 264.9Cr | 379.9Cr | 468.6Cr | 565.1Cr | |||||
Belgium | 38Cr | 20Cr | 30Cr | 34Cr | 47Cr | |||||
Total Assets | 392.8Cr | 379.3Cr | 354.3Cr | 329.5Cr | 325.3Cr | |||||
Ireland | 26Cr | 40Cr | 34Cr | 37Cr | 46Cr | |||||
Total Assets | - | - | - | - | - | |||||
Japan | 22Cr | 21Cr | 23Cr | 54Cr | 44Cr | |||||
Total Assets | 8.6Cr | 7.7Cr | 6.6Cr | 5.6Cr | 5.4Cr | |||||
Germany | 22Cr | 20Cr | 22Cr | 30Cr | 30Cr | |||||
Total Assets | 8.7Cr | 8.1Cr | 7.6Cr | 7.9Cr | 8.1Cr | |||||
Denmark | 12Cr | 13Cr | 16Cr | 32Cr | 28Cr | |||||
Total Assets | 1.5Cr | 1.5Cr | - | - | - | |||||
United Kingdom | 18Cr | 17Cr | 14Cr | 17Cr | 24Cr | |||||
Total Assets | 21Cr | 16Cr | 16Cr | 20Cr | 21Cr | |||||
Rest of Europe | 9.5Cr | 22Cr | 21Cr | 20Cr | 18Cr | |||||
Total Assets | 10L | 10L | 10L | - | - | |||||
Netherlands | 5.6Cr | 7.6Cr | 13Cr | 8.8Cr | 17Cr | |||||
Total Assets | 6.9Cr | 9.2Cr | 11Cr | 27Cr | 29Cr | |||||
China | 25Cr | 14Cr | 16Cr | 17Cr | 15Cr | |||||
Total Assets | 28Cr | 41Cr | 40Cr | 19Cr | 19Cr | |||||
South Korea | 11Cr | 7.9Cr | 14Cr | 9.7Cr | 12Cr | |||||
France | 24Cr | 9.7Cr | 12Cr | 11Cr | 11Cr | |||||
Total Assets | 22Cr | 15Cr | 16Cr | 15Cr | 16Cr | |||||
Sweden | 16Cr | 14Cr | 14Cr | 12Cr | 11Cr | |||||
Canada | 8.4Cr | 8.2Cr | 6.3Cr | 9Cr | 10Cr | |||||
Total Assets | 17Cr | 16Cr | 14Cr | 13Cr | 12Cr | |||||
Rest of Latin America | 2.8Cr | 4.7Cr | 3.8Cr | 2.6Cr | 8Cr | |||||
Italy | 2.8Cr | 3.8Cr | 4.1Cr | 5.2Cr | 6Cr | |||||
Total Assets | - | 20L | 30L | 20L | 20L | |||||
Brazil | 6.4Cr | 6Cr | 4.9Cr | 7.1Cr | 4.9Cr | |||||
Total Assets | 1.8Cr | 1.1Cr | 1.1Cr | 1Cr | 90L | |||||
India | 6.9Cr | 4Cr | 4.2Cr | 4.2Cr | 4.6Cr | |||||
Total Assets | 4.2Cr | 4.3Cr | 3.9Cr | 3.4Cr | 3.7Cr | |||||
Spain | 2.6Cr | 4.4Cr | 4.1Cr | 4Cr | 4.1Cr | |||||
Total Assets | 12Cr | 12Cr | 12Cr | 11Cr | 12Cr | |||||
Singapore | 7.8Cr | 14Cr | 11Cr | 14Cr | 3.2Cr | |||||
Total Assets | 24Cr | 26Cr | 31Cr | 26Cr | 28Cr | |||||
Mexico | 4.7Cr | 3Cr | 3.4Cr | 3.3Cr | 3.1Cr | |||||
Total Assets | 3.1Cr | 3.3Cr | 4.3Cr | 5.4Cr | 5.4Cr | |||||
Rest of Asia | 6.8Cr | 3.1Cr | 3.6Cr | 2.9Cr | 2.8Cr | |||||
Total Assets | 30L | 60L | 50L | 30L | 30L | |||||
Australia & New Zealand | 7.5Cr | 1.7Cr | 2.1Cr | 1.6Cr | 1.7Cr | |||||
Total Assets | 3.7Cr | 80L | 70L | 80L | 70L | |||||
Indonesia | 3.2Cr | 1.8Cr | 1.6Cr | 1.4Cr | 1.2Cr | |||||
Total Assets | 3.4Cr | 3.6Cr | 3.1Cr | 2.9Cr | 1.5Cr | |||||
Thailand | 3.8Cr | 1.7Cr | 1.5Cr | 1.5Cr | 1.2Cr | |||||
Total Assets | 3Cr | 2.7Cr | 2.6Cr | 2.3Cr | 2.4Cr | |||||
Czech Republic | 60L | 70L | 70L | 1.1Cr | 80L | |||||
Total Assets | 1.8Cr | - | - | - | - | |||||
Other Countries | 1.7Cr | 10L | 20L | 20L | 30L | |||||
Total Assets | 30L | 10L | - | 10L | - | |||||
Africa | 1.6Cr | - | - | - | - | |||||
Total Assets | 30L | - | - | - | - | |||||
Rest of North and Central America | 1.3Cr | 10L | 10L | 10L | - | |||||
Total Assets | 30L | 10L | 20L | - | 40L | |||||
New Zealand | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
South Africa | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - | |||||
Rest of North America | - | - | - | - | - |
- Stock Market
- Equities
- LONN Stock
- Financials Lonza Group AG
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















